You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

313 Results
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
New Drug Funding Program
    Pembrolizumab - Locally Recurrent Unresectable or Metastatic Triple Negative Breast Cancer
May 2024
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment of Completely Resected Esophageal or Esophagogastric Junction Cancer
Aug 2024
Document
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
May 2022
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
May 2022
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2022
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment of Urothelial Carcinoma
Aug 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Jul 2023
Regimen
Cancer Type:
Head and Neck, 
Salivary Gland
Intent: Palliative
Jul 2022
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - First-line Treatment of Advanced Gastric, Esophageal, and Esophagogastric Junction Adenocarcinoma
Aug 2024
Drug
Other Name(s): Tepadina®
Jan 2023

Pages